Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;93(1):60.e1-60.e7.
doi: 10.1016/j.anpedi.2020.04.016. Epub 2020 Apr 25.

[Narrative review of the immune response against coronavirus: An overview, applicability for SARS-COV-2, and therapeutic implications]

[Article in Spanish]
Alberto García-Salido  1
Affiliations
Review

[Narrative review of the immune response against coronavirus: An overview, applicability for SARS-COV-2, and therapeutic implications]

[Article in Spanish]
Alberto García-Salido. An Pediatr (Engl Ed). 2020 Jul.

Abstract
in English, Spanish

The new coronavirus (SARS-CoV-2) that causes a severe acute respiratory syndrome emerges in Wuhan, China, in December 2019. It produces the aforementioned disease due to coronavirus 2019 (COVID-19), and has led to a declaration of a world public health emergency by the World Health Organisation. This new SARS-CoV-2 virus could share characteristics and an immune response similar to those described for other coronavirus. Given its activity on the interferon pathway, and the manner in which it dysregulates innate immunity, the use of treatments directed at modulating or containing this could be of interest. A narrative review was made of the current evidence about immunity against coronavirus and its applicability to SARS-CoV-2. The physiopathogenesis is also described, along with the underlying leucocyte activity, with the intention of clarifying the possible usefulness of inflammatory biomarkers and the development of personalised treatments.

El nuevo coronavirus (SARS-CoV-2) productor de síndrome respiratorio agudo severo surge en Wuhan, China, en diciembre de 2019. Genera la denominada enfermedad por coronavirus 2019 (COVID-19) y ha llevado a la declaración de emergencia de salud pública global a la Organización Mundial de la Salud. Este nuevo virus SARS-CoV-2 podría compartir características y respuesta inmune a las descritas para otros coronavirus. Dada su actividad sobre la vía del interferón y el modo en el que disregula la inmunidad innata, el uso de tratamientos dirigidos a modular o contener esta pueden ser de interés. Se realiza una revisión narrativa de la evidencia actual acerca de la inmunidad sobre coronavirus y su aplicabilidad para SARS-CoV-2. Se describe también la fisiopatogenia y la actividad leucocitaria subyacente, con intención de clarificar la posible utilidad de biomarcadores inflamatorios y el desarrollo de tratamientos personalizados.

Keywords: COVID-19; Coronavirus; Immunity; Inmunidad; SARS-CoV-2.

PubMed Disclaimer

References

    1. Khan S., Siddique R., Shereen M.A., Ali A., Liu J., Bai Q. The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options. J Clin Microbiol. 2020;58:e00187-20. - PMC - PubMed
    1. Situación de COVID-19 en España, Ministerio de Sanidad. 2020 [consultado 5 Abr 2020]. Disponible en: https://covid19.isciii.es/
    1. Mizumoto K., Chowell G. Estimating risk for death from 2019 novel coronavirus disease, China. Emerg Infect Dis. 2020;26 - PMC - PubMed
    1. Zhang J.J., Dong X., Cao Y.Y., Yuan Y.D., Yang Y.B., Yan Y.Q. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 - PubMed
    1. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. - PMC - PubMed